Revamped Pharmaceutical Technology Upgradation Assistance Scheme

Purpose:

RPTUAS is a component of the Scheme for Strengthening of Pharmaceuticals Industry. It supports existing pharmaceutical manufacturing units in upgrading facilities to comply with Revised Schedule M and WHO-GMP requirements.

Benefits

• Average turnover from ₹1 crore to below ₹50 crore: 20% of eligible investment.
• Average turnover from ₹50 crore to below ₹250 crore: 15% of eligible investment.
• Average turnover from ₹250 crore to below ₹500 crore: 10% of eligible investment.
• Eligible expenditure may include utilities, clean-room facilities, testing laboratories, stability chambers, waste management, production equipment and consultation or certification expenses.
• Assistance remains subject to the prevailing notified ceiling and latest guidelines.

Key documents:

• Constitution or incorporation documents.
• PAN, GST and statutory registration details.
• Udyam Registration Certificate, where applicable.
• Pharmaceutical manufacturing licence.
• Audited financial statements for the preceding three years.
• Turnover certificate.
• Gap-analysis report.
• Detailed upgradation proposal.
• Machinery quotations and invoices.
• Proof of payment.
• Chartered Accountant-certified expenditure statement.
• Revised Schedule M or WHO-GMP compliance documents.
• Bank details and declarations.

How to apply:

pharma-dept.gov.in/schemes/scheme-strengthening-pharmaceuticals-industry-spi

1. Conduct a gap analysis for Revised Schedule M or WHO-GMP compliance.
2. Prepare the facility-upgradation plan.
3. Apply through the designated portal or Project Management Agency.
4. Upload the gap-analysis report, project details and financial documents.
5. Complete the eligible upgradation activities.
6. Submit Chartered Accountant-certified expenditure statements and compliance evidence.
7. The proposal is examined by the Project Management Agency and Technical Committee before release of assistance.

Eligibility

• Existing pharmaceutical manufacturing units.
• Average turnover below ₹500 crore during the preceding three years.
• Units upgrading facilities for Revised Schedule M or WHO-GMP compliance.
• Only eligible activities and investments specified in current guidelines are considered.

FAQ

Are existing WHO-GMP-certified units eligible?

They may be eligible when undertaking further upgradation to the revised standards, subject to technical evaluation.

Is a particular bank compulsory?

No particular bank is exclusively linked to the revamped subsidy scheme.

Is there a cap on total investment?

The cited FAQ states that there is no cap on investment, but Government assistance is restricted to the applicable ceiling.

Beneficiary:

As mentioned above

Benefits:

Capital subsidy for eligible technology and facility upgradation undertaken by pharmaceutical manufacturing units.